Four EU Biotechs Raise Extra Funds In Year-End Scramble
This article was originally published in The Pink Sheet Daily
Executive Summary
European biotechs tap investors for extra funding to support development plans.
You may also be interested in...
ThromboGenics Delays Diabetic Retinopathy Study; On Track To File Ocriplasmin For Retinal Adhesions
Belgian company focuses on filing orciplasmin for U.S. and EU approval, and preparing for commercialization.
ThromboGenics Delays Diabetic Retinopathy Study; On Track To File Ocriplasmin For Retinal Adhesions
Belgian company focuses on filing orciplasmin for U.S. and EU approval, and preparing for commercialization.
Deals Of The Week: J&J/Crucell, Merck/Beijing Genomics Institute …
Each week, “The Pink Sheet” presents commentary on some of the week’s most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at http://invivoblog.blogspot.com.